DiagnoCure announces the filing of a final short form prospectus



    /NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR DISSEMINATION IN THE
    UNITED STATES/

    Ticker Symbol: CUR

    QUEBEC CITY, March 27 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR)
("DiagnoCure") is pleased to announce that it has filed a final short form
prospectus with the securities authorities in all provinces of Canada in
connection with the previously announced public offering of 5,850,000 common
shares in the share capital of DiagnoCure.
    This offering is being made through a syndicate of underwriters led by
National Bank Financial Inc. and including Orion Securities Inc., Canaccord
Capital Corporation and Industrial Alliance Securities Inc. for the offering
of the common shares.
    The offering is subject to normal regulatory approvals including approval
of the Toronto Stock Exchange and is expected to close on or before April 3,
2007.
    The proceeds from the offering will be used to support the implementation
of the Company's business plan, namely to expand the product portfolio and
acquire or in-license additional cancer diagnostic products.

    The securities offered have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold within the
United States absent registration or an exemption from the registration
requirements thereunder. This release does not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of the
securities in any state in which such offer, solicitation or sale would be
unlawful.

    About DiagnoCure

    DiagnoCure specializes in the development, production and
commercialization of molecular diagnostics for the detection and management of
cancer. Its first test, ImmunoCyt(TM) / uCyt+(TM) for bladder cancer, is
distributed worldwide. In 2003, the Company entered into a strategic alliance
with Gen-Probe (NASDAQ:   GPRO) for the development and commercialization of a
second generation PCA3-based diagnostic test for prostate cancer. This test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagent (ASR) as well as in Europe as a CE-marked in vitro assay. The Company
plans to expand its product portfolio, namely in prostate, lung and other
cancers. In addition to its own research, the Company intends to acquire or
in-license promising cancer biomarkers from both academic and commercial
institutions. Additional information can be found at www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects and future revenues are based on
management expectations. In addition, the reader is referred to the applicable
general risks and uncertainties described in DiagnoCure's most recent Annual
Information Form under the heading "Risk Factors". DiagnoCure undertakes no
obligation to publicly update or revise any forward-looking statements
contained herein.




For further information:

For further information: Thom Skinner, Chief Financial Officer,
DiagnoCure Inc., (418) 527-6100, communications@diagnocure.com

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890